Oral Treatment for COVID-19 Gains Fast Track Designation
EDP-235 is currently being examined in a first-in-human phase 1 trial to assess safety, tolerability, and pharmacokinetics.
EDP-235 is currently being examined in a first-in-human phase 1 trial to assess safety, tolerability, and pharmacokinetics.
Observational findings from several other age groups indicate a high level of protection with the 3-dose regimen.
The approval is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Belimumab is already indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus in individuals aged 5 years and over.
The NIAID has launched a new study aimed at accelerating the most promising therapies in the fight against coronavirus disease 2019.
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the FDA
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The FDA Advil Dual Action with Acetaminophen for the temporary relief of minor aches and pains due to arthritis and more.
Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo®.